Actively Recruiting
Pilot Study of RR-HNK in OCD
Led by Carolyn Rodriguez · Updated on 2026-03-05
45
Participants Needed
1
Research Sites
201 weeks
Total Duration
On this page
Sponsors
C
Carolyn Rodriguez
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
CONDITIONS
Official Title
Pilot Study of RR-HNK in OCD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages 18-65
- Diagnosed with obsessive-compulsive disorder (OCD)
- Have failed at least one prior standard OCD treatment (such as SRI medication or cognitive behavioral therapy) or have refused these treatments for personal reasons
- Agree to lifestyle changes including fasting before infusion, avoiding other interventional trials during this study, and following medication procedures
- Able to provide informed consent
You will not qualify if you...
- Allergy or hypersensitivity to ketamine
- Any current or past medical or psychiatric condition that makes participation unsafe as judged by the investigator or study doctor
- Pregnant, nursing, or able to become pregnant without effective birth control
- History of deep brain stimulation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University School of Medicine
Palo Alto, California, United States, 94305
Actively Recruiting
Research Team
I
Izzy Vo, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here